Drug Interaction Report
1 potential interaction and/or warning found for the following 2 drugs:
- Anturane (sulfinpyrazone)
- urokinase
Interactions between your drugs
sulfinpyrazone urokinase
Applies to: Anturane (sulfinpyrazone), urokinase
MONITOR CLOSELY: Drugs that inhibit platelet function may increase the risk of bleeding when administered prior to, during, or after thrombolytic therapy.
MANAGEMENT: Careful monitoring for signs of bleeding, particularly at arterial puncture wounds, is recommended when thrombolytics are used concurrently or sequentially with antiplatelet agents. Some authorities recommend avoiding the initiation of platelet aggregation inhibitors within the first 24 hours following thrombolysis treatment. Local guidelines and prescribing information for individual thrombolytic drugs should be consulted for further recommendations.
References (8)
- (2001) "Product Information. Ticlid (ticlopidine)." Syntex Laboratories Inc
- (2001) "Product Information. Abbokinase (urokinase)." Abbott Pharmaceutical
- (2001) "Product Information. Activase (alteplase)." Genentech
- (2001) "Product Information. Streptase (streptokinase)." Astra-Zeneca Pharmaceuticals
- (2001) "Product Information. Retavase (reteplase)." Boehringer Mannheim
- (2001) "Product Information. TNKase (tenecteplase)." Genentech
- Harder S, Klinkhardt U (2000) "Thrombolytics: drug interactions of clinical significance." Drug Saf, 23, p. 391-9
- Hirsch J, Dalen J, Guyatt G, American College of Chest Physicians (2001) "The sixth (2000) ACCP guidelines for antithrombotic therapy for prevention and treatment of thrombosis. American College of Physicians." Chest, 119(1 Suppl), 1S-2S
Drug and food interactions
No alcohol/food interactions were found with the drugs in your list. However, this does not necessarily mean no food interactions exist. Always consult your healthcare provider.
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Report options
- Switch to consumer interaction data
- Email this report to a friend, doctor, or patient
- Ask questions, find answers
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Decadron
Decadron is used for addison's disease, adrenal insufficiency, adrenocortical insufficiency ...
Dexamethasone Intensol
Dexamethasone Intensol is used for addison's disease, adrenal insufficiency, adrenocortical ...
Taltz
Taltz (ixekizumab) is used to treat plaque psoriasis, psoriatic arthritis, and ankylosing ...
Deltasone
Deltasone is used for acute lymphocytic leukemia, adrenocortical insufficiency, allergic reactions ...
Zyloprim
Zyloprim is used for calcium oxalate calculi with hyperuricosuria, gout, hyperuricemia secondary to ...
Kenalog-40
Kenalog-40 is a long-acting corticosteroid injection for intramuscular (into the muscle) or ...
Uloric
Uloric (febuxostat) reduces the production of uric acid in your body and is used to treat gout ...
Rayos
Rayos (prednisone, delayed-release) is used to treat rheumatoid arthritis, polymyalgia rheumatica ...
Zilretta
Zilretta (triamcinolone injection) is used for the management of osteoarthritis pain of the knee ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.